Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Change in Inventory (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Change in Inventory for 5 consecutive years, with $13.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Inventory rose 682.86% year-over-year to $13.5 million, compared with a TTM value of $28.5 million through Dec 2025, up 699.64%, and an annual FY2025 reading of $28.5 million, up 699.64% over the prior year.
  • Change in Inventory was $13.5 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from -$6.8 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $26.1 million in Q2 2025 and bottomed at -$6.8 million in Q3 2025.
  • Average Change in Inventory over 5 years is $2.7 million, with a median of $1.1 million recorded in 2023.
  • The sharpest move saw Change in Inventory plummeted 583.23% in 2022, then soared 1322.14% in 2024.
  • Year by year, Change in Inventory stood at -$1.9 million in 2021, then surged by 461.37% to $7.0 million in 2022, then dropped by 20.62% to $5.5 million in 2023, then plummeted by 141.81% to -$2.3 million in 2024, then soared by 682.86% to $13.5 million in 2025.
  • Business Quant data shows Change in Inventory for KNSA at $13.5 million in Q4 2025, -$6.8 million in Q3 2025, and $26.1 million in Q2 2025.